



IBA Launches Next Generation COMPASS Two-In-One Radiation Therapy Plan Verification System at AAPM

COMPASS provides needed flexibility for optimal QA efficiency enabling Measurement- as well as full 3D Calculation-Based independent treatment plan verification.

Indianapolis, Indiana, August 1st, 2013 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of a milestone: COMPASS 3.0 plan verification system. COMPASS, the first patient anatomy- centric and most sophisticated solution for advanced IMRT and rotational plan verification now provides a new two-in-one solution: calculation-based full 3D independent Treatment Plan System (TPS) verification and measurement-based Quality Assurance (QA) for the complete treatment chain, including linear accelerators. COMPASS offers superior full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need. This announcement will be made at the 55th American Association of Physicists in Medicine Annual Meeting and Exhibition, Booth 1035.

The new COMPASS also provides crucial calculation time saving and therefore much faster QA workflows. Dose calculations of 7 beam IMRT plans are done in just one minute, and more sophisticated 1 arc VMAT plans in just over two minutes.

“We started using COMPASS clinically in May of 2012, and to date it has been used with confidence to verify the deliverability of over 500 IMRT and RapidArc plans at our centre,” said Ryan Rivest, Medical Physicist at Cancer Care in Manitoba, Canada. “We have recently tested the new COMPASS and are excited about many of the changes, including a more efficient beam modelling process and significantly faster dose calculation”.

With its powerful Collapsed Cone Algorithm for independent dose calculations, COMPASS allows TPS-class dose calculations on real patient CT as well as real patient CT-based DVH, and 3D Gamma. Independent beam modelling of individual linacs enables flexibility in precisely modelling as many machines as needed for highly accurate plan verifications. Physicists can measure and compare real linac delivery vs. TPS-planned delivery as well as analyze the effect of segment errors on the total treatment accuracy. Plan verification is a crucial step in radiation therapy to ensure treatment accuracy and patient dose safety, and COMPASS is designed to support healthcare professionals in a highly comprehensive and efficient way.

“We are excited to launch the next, best yet COMPASS, our new two-in-one solution offering significant enhancements, that we feel is the most robust patient plan verification system available today. After receiving extremely positive feedback from many COMPASS customers, we are confident that the new COMPASS is a huge step forward in the field of plan verification and providing safer radiation therapy”, remarked Ralf Schira, Vice President of Marketing for IBA Dosimetry.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems.



IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

Media Contact:

Suzanne Shankle
Marketing Specialist
IBA Dosimetry
3150 Stage Post Drive, Suite 110
Bartlett, TN 38133
Tel: (901) 386-2242
Suzanne.shankle@iba-group.com

<http://www.iba-dosimetry.com>

Press release | **August 1, 2013**

###